SecBot SecBot
PRESS-RELEASE ·Filed Jun 28, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a transformative catalyst for BBIO. The PROPEL 3 data are best-in-class across all key endpoints with a clean safety profile, and the NEJM publication adds credibility. NDA submission in Q3 2026 and potential approval/launch in early to mid 2027 provide a clear regulatory catalyst timeline. Monitor for any FDA filing acceptance or priority review designation. The stock may gap up significantly on this data release.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$72.01
T+0 close · Jun 28, 2026 · via day close
Latest settled
−3.86%
T+60 · $69.23
Vs SPY
−8.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $72.01entry
  2. T+1 · 5mo ago +3.43%α +2.65% · $74.48
  3. T+5 · 4mo ago +7.97%α +6.58% · $77.75
  4. T+20 · 4mo ago +16.68%α +16.96% · $84.02
  5. T+60 · 8w ago −3.86%α −8.25% · $69.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, published in NEJM and presented at ICCBH. The drug met primary and key secondary endpoints with the largest annualized height velocity improvement in any Phase 3 achondroplasia study and first statistically significant body proportionality improvement. NDA submission to FDA is planned for Q3 2026 with US launch anticipated in early to mid 2027.

Key Facts

  • Phase 3 PROPEL 3 met primary endpoint: LS mean treatment difference in annualized height velocity +1.74 cm/yr (p<0.0001); observed mean difference +2.10 cm/yr
  • Key secondary endpoint met: height Z-score LS mean increase +0.41 SD (p<0.0001)
  • First statistically significant body proportionality improvement in achondroplasia: LS mean treatment difference -0.05 (p<0.05) in children <8 years
  • New arm span Z-score data: LS mean +0.37 SD vs placebo (p<0.0001), first statistically significant result in a placebo-controlled achondroplasia trial
  • No discontinuations or serious adverse events related to study drug; 3 mild transient hyperphosphatemia cases (4%)
  • Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from FDA; potential Priority Review Voucher if approved
  • NDA submission planned Q3 2026; US launch anticipated early to mid 2027; MAA to EMA in H2 2026

Financial Impact

Achondroplasia affects ~55,000 people in US and EU, including up to 10,000 children with open growth plates. First-in-class oral therapy with best-in-class efficacy data positions infigratinib for significant commercial opportunity. No revenue or deal values disclosed.

revenuemarket share

Risk Factors

  • Regulatory risk: FDA may request additional data or have concerns about the NDA package despite Breakthrough Therapy designation
  • Competition: existing injectable therapy (Vosoritide) and other oral candidates in development could limit market share
  • Commercial execution risk: launch in early to mid 2027 requires successful manufacturing, pricing/reimbursement, and market access
  • Dilution risk: potential need for additional capital to fund launch and pipeline, though market cap of $13.7B provides flexibility

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3318616

Track record

38 reports on BBIO

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 28, 2026